Multaq Approval History

• FDA approved: Yes (First approved July 1st, 2009)
• Brand name: Multaq
• Generic name: dronedarone
• Company: Sanofi-aventis
• Treatment for: Atrial Fibrillation, Atrial Flutter

Multaq (dronedarone) is antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter.

FDA Approval History for Multaq

Date	Article
Jul  2, 2009	FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Mar 19, 2009	FDA Advisory Committee Recommends Approval of Multaq (dronedarone)
Aug  8, 2008	Multaq (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation

See also...

Multaq (dronedarone) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.